Healthy Skepticism Library item: 6011

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Cheng M.
New study raises concerns over the use of drug-coated coronary stents
Canadian Press 2006 Sep 3
http://ca.news.yahoo.com/s/03092006/2/xhealth-new-study-raises-concerns-use-drug-coated-coronary-stents.html

Full text:

New study raises concerns over the use of drug-coated coronary stents
Sun Sep 3, 3:32 PM

By Maria Cheng

BARCELONA, Spain (AP) – Experts expressed concerns Sunday that drug-coated heart stents once heralded as revolutionary may, in rare instances, lead to potentially fatal blood clots.

Studies released Sunday at the World Cardiology Congress in Barcelona raised new concerns about the risks that may accompany the drug-coated stents, which were introduced in 2000 as an improvement on bare-metal stents – the metal-mesh tubes used to prop open coronary arteries.

Nearly six million people worldwide now have the drug-lined versions. The devices are intended to keep arteries open after having been cleared of fatty deposits and are often credited with saving patients from future heart attacks or bypass surgery.

A Swiss-Dutch study tracked 8,146 patients and found that recipients of drug-coated stents were at increased risk of thrombosis, or blood clots, that can occasionally result in death.

Two other Swiss studies analysing information discussed at the cardiology conference also found that first-generation drug-coated stents had higher links to thrombosis as compared with bare-metal stents.

Some medical experts worry that the financial implications of reducing usage of the profitable drug-coated stents may be taking priority over improving patients’ health.

“It’s time to stop and re-evaluate,” said Dr. Salim Yusef, professor of medicine and director of cardiology at McMaster University in Hamilton.

Yusef questioned whether the wide use of drug-coated stents was a panacea or a trojan horse.

“Having done six million of these procedures, isn’t it a terrible indictment on us that we don’t have long-term safety data on these?” he asked.

The drug-coated stent market last year was estimated as being worth more than $5.5 billion Cdn and is dominated by Boston Scientific and Johnson & Johnson. Drug-coated stents are far more profitable then the plain kind, selling for about $2,550 each compared with less than $800 for bare-metal versions.

In bare-metal stents, heart cells naturally grow to cover the stent, providing a natural biological lining. But in the drug-coated versions, the drugs prevent tissue growth – which is both their intent and their possible downfall.

Drug-coated stents were previously viewed as a great advance since the drugs they emitted prevented cells that could block the arteries from growing. A thick growth of cells is undesirable, but a thin layer of cells lining the artery is essential. In some instances, drug-coated stents have prevented this minimal protective cell layer from growing, leaving exposed metal, which essentially can act as a clot magnet.

“This is potentially explosive information,” said Dr. Steven Nissen, president of the American College of Cardiology and director of cardiology at the Cleveland Clinic.

“It certainly makes me pause with substantial concern,” said Nissen, who said there is already a shift developing in the U.S. away from using the drug-coated stents in favour of their uncoated predecessors.

Doubts about drug-coated stents were initially raised in March by a small-scale Swiss study, though there have long been naysayers about their potential adverse effects. Results from the Swiss-Dutch study found that the incidence of thrombosis does not diminish as time passes. Researchers found that the possibility of thrombosis continued to pose a risk, though minimal, during the first three years following stent implantation. Other issues, however, such as patient compliance with taking prescribed medications, may play a role in blood clot formation.

While significant, these new findings aren’t expected to radically alter the use of drug-coated stents in the immediate future.

“This won’t change clinical practice right now, but it shows us that this a problem that needs to be investigated with larger trials,” said Dr. Raymond Gibbons, president of the American Heart Foundation.

Nissen, however, was more skeptical. “There is a tendency for physicians to switch practices even before data is solid,” he explained. “If there’s a suspicion, why take the risk?”

Copyright 2006 © Yahoo! Inc. All rights reserved.